Purdue Abuse Study May Create Ongoing Challenge For Generic Entry
This article was originally published in The Pink Sheet Daily
Executive Summary
OxyContin’s three-year data exclusivity for study of intranasal liking might be just the beginning of labeling hurdles for ANDAs.
You may also be interested in...
Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims
Abuse-deterrent opioids address a serious unmet need and help differentiate brands from the field of generics, but so far Purdue’s OxyContin remains the only opioid on the market with abuse-deterrent claims, even though FDA recently approved two new opioid analgesics.
OxyContin Revised Labeling Expects Less Abuse Via Injection, Snorting
There will be no generics of original OxyContin; FDA says it can no longer serve as a reference product because it has a greater abuse potential than the reformulation, where Purdue has secured particularly strong language regarding reducing intranasal abuse.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.